With the removal of Relyvrio (sodium phenylbutyrate/taurursodiol) from the market, Amylyx Pharmaceuticals, Inc. will lose its sole commercial revenue stream and return its focus to pipeline development. The company announced on 4 April that it will withdraw Relyvrio from the US and Canada, where it is sold as Albrioza, immediately due to lack of efficacy for amyotrophic lateral sclerosis (ALS).
Amylyx Resets As A Clinical-Stage Company, Withdrawing Relyvrio
Workforce Will Be Cut By 70%
The ALS treatment Relyvrio was removed from the market as expected following a Phase III trial failure.
